What is IFM’s Reversing Cognitive Decline Training?
Alzheimer’s disease (AD) is the leading cause of dementia worldwide and is poised to become a major public health crisis. To date, there are few single treatments, pharmaceutical or otherwise, that can help with this degenerative condition.
IFM's Reversing Cognitive Decline Training
Dale Bredesen, MD
On March 11-12, 2017, The Institute for Functional Medicine, in collaboration with Dale Bredesen, MD
, and MPI Cognition, presented a two-day program with an exciting new approach to the treatment of early stage AD and mild cognitive impairment (MCI).
During this program, attendees learned a multi-pronged treatment strategy. Using a systems biology approach, attendees learned:
- Assessment of patients for MCI and early AD
- Stratification of patients by root cause
- Application of a multimodal protocol to individualize treatments for each patient that address the appropriate underlying causes.
Clinicians trained in this protocol can arrest cognitive decline and in many cases even reverse it.
Clinical Competencies Acquired by These Clinicians
- Recognize MCI and early dementia due to AD and differentiate types of cognitive decline, including non-Alzheimer's dementia.
- Evaluate the physiological underpinnings of MCI and early AD and the rationale for the multimodal systems approach to treatment.
- Differentiate between the six major subtypes of MCI/early AD and select appropriate laboratory tests to evaluate the major contributors to each patient’s dysfunction.
- Explain the critical role of the collaborative care team approach in successfully treating MCI and early AD.
- Evaluate the importance of technological advances including neuroimaging, cognitive assessments, and therapeutic cognitive training in assessing and treating MCI and early AD.